Navigation Links
Largest coronary artery disease study shows evidence of link between inflammation and heart disease
Date:12/4/2012

OTTAWA, December 3, 2012 The University of Ottawa Heart Institute (UOHI) participated in the largest genetic study of Coronary Artery Disease (CAD) to date. Researchers from the CARDIoGRAMplusC4D Consortium report the identification of 15 genetic regions newly associated with the disease, bringing to 46 the number of regions associated with CAD risk.

The Ruddy Canadian Cardiovascular Genetics Centre, at the Heart Institute, was the main genetic centre in Canada contributing most patient cases involved in this study and analyzing patient cases from across North America.

In this unparalleled study, published today in the prestigious scientific magazine Nature, the team identified a further 104 independent genetic variants that are very likely to be associated with the disease, enhancing our knowledge of the genetic component that causes CAD.

Researchers, including Dr. George Wells and Dr. Alexandre Stewart from the Heart Institute, used their discoveries to identify biological pathways that underlie the disease and showed that lipid metabolism and inflammation play a significant role in CAD.

CAD and its main complication, myocardial infarction (heart attack), are some of the most common causes of death in the world and approximately one in five men and one in seven women die from the disease in the UK. CAD has a strong inherited basis.

"These findings show, for the first time, clear evidence that several of the genetic risk factors for CAD function through known inflammatory pathways," said Dr. Robert Roberts, President and CEO of the Heart Institute and Director of the Ruddy Canadian Cardiovascular Genetics Centre. "This identifies a novel pathway for the prevention of heart disease and establishes molecules that can now be targeted for developing new therapies."

The Consortium spanning over 180 researchers from countries across Europe (UK, Germany, Iceland, Sweden, Finland, France, Italy, Greece), Lebanon, Pakistan, Korea, USA and Canada analyzed DNA from over 60,000 CAD cases and 130,000 apparently unaffected people. The researchers integrated the genetic findings into a network analysis and, unsurprisingly, found the metabolism of fats being the most prominent pathway linked to CAD. The second most prominent pathway, however, was inflammation which provides evidence at the molecular level for the link between inflammation and heart disease.

The importance of the work is that while some of the genetic variants that were identified work through known risk factors for CAD such as high blood pressure and cholesterol, many of the variants appear to work through unknown mechanisms. Understanding how these genetic variants affect CAD risk is the next goal and this could pave a way to developing new treatments for this important disease.

This study provides a useful framework for future projects to elucidate the biological processes underlying CAD and to investigate how genes work together to cause this disease.


'/>"/>
Contact: Vincent Lamontagne
vlamontagne@ottawaheart.ca
613-899-6760
University of Ottawa Heart Institute
Source:Eurekalert

Related medicine news :

1. Smallest, Largest Fetuses at Higher Risk of Stillbirth
2. OnPage Provides Secure, Rapid Response at New England’s Largest Catholic Hospital
3. HIV suppression not as good as previously thought, largest study of viral-load blood tests show
4. Largest review of management and treatment of Barretts dysplasia and adenocarcinoma
5. Worlds largest meeting of ear, nose, and throat doctors
6. Worlds largest respiratory genetics study launches on World COPD Day
7. Coronary rehabilitation programs in Europe are underused
8. Diagnostic test shows potential to noninvasively identify significant coronary artery disease
9. Advanced CT scans accurately assess coronary blockages
10. Perceived control affects complication rates in patients with acute coronary syndrome
11. Bypass surgery improves survival for patients with diabetes and multi-vessel coronary artery disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: